Brief Report: Three-Year Overall Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC - Update From PACIFIC
Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2019.10.002
Full Text
Open PDFAbstract
Available in full text
Date
February 1, 2020
Authors
Publisher
Elsevier BV